Leukemia and Lymphoma Program

Physicians and researchers at the Cancer and Blood Diseases Institute of Cincinnati Children’s Hospital Medical Center offer clinical research studies for patients with leukemia and lymphoma.

View a complete list of current clinical trials or narrow your search specifically for those related to leukemia and lymphoma.

Acute Lymphoblastic Leukemia

Therapy for First Relapse

• 20140106-CFZ008: Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia 
• ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
• T2012-002-MARQIBO: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
• AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
• 20130320-BITE: An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Rialto Study)
• AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Therapy for Newly Diagnosed Very High Risk Disease

• TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
• AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
• AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
• ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)

Therapy for Second or Greater Relapse

• KTE-C19-104: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
• AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) 
• 20140106-CFZ008: Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
• ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
• T2012-002-MARQIBO: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
• CLDK378X2103: A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies that have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
• CPX-MA-1201: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies
• 20130320-BITE: An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Rialto Study)
• AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia and Myelodysplasia

Therapy for New Diagnosis High Risk Disease

• AAML1331: A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid

Therapy for Relapse

• ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
• AAML1522: A Phase II, Multicenter, single-arm, open label study to evaluate the activity, safety, and pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric subjections from 1 to 18 Years of age with Relapseor Refractory Acute Myeloid Leukemia
• CPX-MA-1202: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies
• AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)

Hodgkin's and Non-Hodgkin's Lymphoma

Therapy for Relapse

• ADVL1514: A Phase 1 study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan 
• ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
• ADVL1513: A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
• EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
• ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND#125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
• ADVL1412: A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
• AHOD1221: A Phase I/II Study of Brentuximab Vendotin in combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
• CPX-MA-1202: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies
• ADVL1621: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
• LOXO-TRK-15003: A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
• SPOC-2012-001: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors